In genetically modified mice, tumours appeared more often or grew larger after gamma-delta T cells lost the receptor that acts as their molecular antenna. The same disruption weakened the tumour-fighting ability of human cells grown in the laboratory. The result identifies an ongoing requirement for immune surveillance, not a one-time instruction received during cell development.
The international study was published in Nature and co-led by the Francis Crick Institute in the United Kingdom and the Universidad Complutense de Madrid. Researchers from the Centro de Biología Molecular Severo Ochoa, CBM-CSIC-UAM, also took part. The work adds to evidence that the ongoing anti-tumour activity of these rapid-response cells depends on an adaptive T-cell receptor, even though their behaviour often resembles innate immune defence.
Gamma-delta T cells are concentrated in tissues such as the skin and intestine. They monitor their surroundings and can react when they encounter infected cells. They also respond to damaged tissue or cells behaving abnormally. Their surface receptor receives signals from the local environment and helps determine whether the cells remain ready to respond.
The study shifts the timing question. Scientists already knew that the receptor mattered while these immune cells were developing. The new work shows that the signal must continue after the cells mature and settle in tissues. Without it, they remain present but lose traits needed to stay in place and activate properly. They also become less able to react to damage. The Nature study links tissue surveillance to receptor signalling in real time, not to developmental programming alone.
Researchers designed the experiment to separate development from maintenance. They used genetically modified mice in which the receptor could be removed only after gamma-delta T cells had fully developed and reached tissues. Once the receptor was switched off, the cells rapidly changed their behaviour and internal biological processes.
The result was not confined to mice.
In laboratory cultures of human gamma-delta T cells, removing the receptor produced comparable changes. The affected processes involved defensive activity and the cells’ internal functioning. Human cells without a working receptor were less able to restrain the growth of melanoma and colorectal cancer cells in laboratory experiments. The findings also suggested that the need for a working receptor is not limited to one tissue or one subtype of gamma-delta T cell.
The cancer tests used three separate models involving skin and colon tumours. Animals whose gamma-delta T cells lacked the receptor developed tumours more frequently or showed greater tumour growth than animals whose cells retained it. Human cells with the receptor removed were also less able to restrain tumour-cell growth in laboratory conditions.
This mechanism helps explain why these immune cells can respond quickly. Their readiness depends on continuous contact with signals from surrounding tissue, not on developmental programming alone. A related report examined the same vulnerability through weakened tumour-fighting activity.
Miguel Muñoz of the CBM-CSIC-UAM said the receptor is needed to start the cells during development and keep them receiving environmental signals after they settle in tissues. That distinction matters because disabling the receptor left the cells in place. It changed their ability to remain functional where the body needs them.
The immediate significance is scientific rather than therapeutic. The CSIC stresses that the work is basic research and does not itself constitute a new cancer treatment. Its value lies in identifying a condition future immunological strategies may need to preserve: gamma-delta T cells must keep their molecular antenna active when they confront abnormal tissue. Any therapeutic approach would so need to account for receptor activity during and after cell preparation, including conditions encountered in a tumour.
The receptor is a developmental switch and part of the cells’ continuing defence system. Until this mechanism is translated into tested therapies, it should not be presented as a clinical breakthrough. The evidence comes from genetically modified mouse models and human cell cultures, establishing a biological mechanism and a possible therapeutic direction, not efficacy in patients.
